Technologies

Portfolio Driven by Variety of Technology Platforms

Through a combination of research and acquisitions, Ligand has created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.

OmniAb®

Summary

Four OmniAb® therapeutic antibody platforms, OmniRat®, OmniFlic®, OmniMouse® and OmniChicken™, that produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.

More about this technology »

Licensing Contact

Captisol®

Summary

Captisol® is a patent-protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

More about this technology »

Licensing Contact

LTP Technology™

Summary

LTP Technology™ is a broadened novel pro-drug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver.

More about this technology »

Licensing Contact

Pelican Expression Technology

Summary

Ligand’s Pelican Expression Technology platform is utilized to develop next-generation and novel protein therapeutics, to improve existing therapies and create new therapies for biological targets linked to critical, unmet diseases. The proprietary platform uses P. fluorescens bacterium, which are especially well-suited for complex, large-scale protein production that cannot be made by more traditional host systems. The technology can contribute significant value to biopharmaceutical development programs by reducing development timelines and costs for manufacturing human therapeutics and vaccines

More about this technology »

Licensing Contact

Icagen Ion Channel Technology

Summary

The Icagen Ion Channel Technology Platform is a novel drug discovery platform which enables drug discovery targeting ion channels and transporters. These proteins are key components in a wide variety of biological processes that involve regulation of cells and we believe have broad therapeutic applicability including cancer, metabolic disease, pain, neurological diseases, infectious diseases and others.

Licensing Contact